The US FDA has approved Pfizer’s vaccine Penbraya for ages 10 to 25, offering protection against the five main types of bacteria causing meningitis and blood poisoning. As a two-dose vaccine administered six months apart, it combines elements of Trumenba and Menveo and reduces the current four-dose regimen for full protection. The CDC will discuss recommendations for Penbraya’s use in adolescents and young adults.
Critical insights Q&A: Anomali’s AI-native approach helps defenders cut noise, mitigate swiftly
The cybersecurity world is deep into an AI pivot. Related: The case for AI-native SOCs The headlines fixate on doomsday threats and autonomous cyber weapons.
